196 related articles for article (PubMed ID: 17554040)
1. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases.
Sperka T; Miklóssy G; Tie Y; Bagossi P; Zahuczky G; Boross P; Matúz K; Harrison RW; Weber IT; Tözsér J
J Gen Virol; 2007 Jul; 88(Pt 7):2052-2063. PubMed ID: 17554040
[TBL] [Abstract][Full Text] [Related]
2. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.
Kádas J; Weber IT; Bagossi P; Miklóssy G; Boross P; Oroszlan S; Tözsér J
J Biol Chem; 2004 Jun; 279(26):27148-57. PubMed ID: 15102858
[TBL] [Abstract][Full Text] [Related]
3. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.
Bagossi P; Sperka T; Fehér A; Kádas J; Zahuczky G; Miklóssy G; Boross P; Tözsér J
J Virol; 2005 Apr; 79(7):4213-8. PubMed ID: 15767422
[TBL] [Abstract][Full Text] [Related]
4. Different Mutation Tolerance of Lentiviral (HIV-1) and Deltaretroviral (BLV and HTLV) Protease Precursors.
Mótyán JA; Kassay N; Matúz K; Tőzsér J
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146695
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of activity of the protease from bovine leukemia virus.
Ménard A; Leonard R; Llido S; Geoffre S; Picard P; Berteau F; Precigoux G; Hospital M; Guillemain B
FEBS Lett; 1994 Jun; 346(2-3):268-72. PubMed ID: 8013645
[TBL] [Abstract][Full Text] [Related]
6. Solid phase synthesis of the proteinase of bovine leukemia virus. Comparison of its specificity to that of HIV-2 proteinase.
Bláha I; Tözsér J; Kim Y; Copeland TD; Oroszlan S
FEBS Lett; 1992 Sep; 309(3):389-93. PubMed ID: 1325379
[TBL] [Abstract][Full Text] [Related]
7. Modelling, synthesis and biological activity of a BLV proteinase, made of (only) 116 amino acids.
Précigoux G; Geoffre S; Léonard R; Llido S; Dautant A; d'Estaintot BL; Picard P; Ménard A; Guillemain B; Hospital M
FEBS Lett; 1993 Jul; 326(1-3):237-40. PubMed ID: 8392000
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases.
Tözsér J; Zahuczky G; Bagossi P; Louis JM; Copeland TD; Oroszlan S; Harrison RW; Weber IT
Eur J Biochem; 2000 Oct; 267(20):6287-95. PubMed ID: 11012683
[TBL] [Abstract][Full Text] [Related]
9. Highly specific inhibition of leukaemia virus membrane fusion by interaction of peptide antagonists with a conserved region of the coiled coil of envelope.
Lamb D; Schüttelkopf AW; van Aalten DM; Brighty DW
Retrovirology; 2008 Aug; 5():70. PubMed ID: 18680566
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck ZQ; Lin YC; Elder JH
J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
[TBL] [Abstract][Full Text] [Related]
11. Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.
Eizert H; Bander P; Bagossi P; Sperka T; Miklóssy G; Boross P; Weber IT; Tözsér J
J Virol; 2008 Oct; 82(20):10111-7. PubMed ID: 18701588
[TBL] [Abstract][Full Text] [Related]
12. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase.
Hrusková-Heidingsfeldová O; Bláha I; Urban J; Strop P; Pichová I
Leukemia; 1997 Apr; 11 Suppl 3():45-6. PubMed ID: 9209292
[TBL] [Abstract][Full Text] [Related]
13. Substrates and inhibitors of human T-cell leukemia virus type I protease.
Ding YS; Rich DH; Ikeda RA
Biochemistry; 1998 Dec; 37(50):17514-8. PubMed ID: 9860866
[TBL] [Abstract][Full Text] [Related]
14. Bovine leukemia virus nucleocapsid protein is an efficient nucleic acid chaperone.
Qualley DF; Sokolove VL; Ross JL
Biochem Biophys Res Commun; 2015 Mar; 458(3):687-692. PubMed ID: 25686502
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Expression and Latency in BLV and HTLV.
Pluta A; Jaworski JP; Douville RN
Viruses; 2020 Sep; 12(10):. PubMed ID: 32992917
[No Abstract] [Full Text] [Related]
16. Bovine leukemia virus: purification and characterization of the aspartic protease.
Menard A; Mamoun RZ; Geoffre S; Castroviejo M; Raymond S; Precigoux G; Hospital M; Guillemain B
Virology; 1993 Apr; 193(2):680-9. PubMed ID: 8384751
[TBL] [Abstract][Full Text] [Related]
17. Analysis of substrate cleavage by recombinant protease of human T cell leukaemia virus type 1 reveals preferences and specificity of binding.
Daenke S; Schramm HJ; Bangham CR
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2233-9. PubMed ID: 8077922
[TBL] [Abstract][Full Text] [Related]
18. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM
Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331
[TBL] [Abstract][Full Text] [Related]
19. Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo.
Gatot JS; Callebaut I; Van Lint C; Demonté D; Kerkhofs P; Portetelle D; Burny A; Willems L; Kettmann R
J Virol; 2002 Aug; 76(16):7956-67. PubMed ID: 12134000
[TBL] [Abstract][Full Text] [Related]
20. Cross-activation of the Rex proteins of HTLV-I and BLV and of the Rev protein of HIV-1 and nonreciprocal interactions with their RNA responsive elements.
Felber BK; Derse D; Athanassopoulos A; Campbell M; Pavlakis GN
New Biol; 1989 Dec; 1(3):318-28. PubMed ID: 2562124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
